Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Pharmaceuticals' products are constantly in high demand. The company's portfolio should help drive revenue growth for a while. It also has an exciting pipeline that will help it diversify ...

25 analysts have shared their evaluations of Vertex Pharmaceuticals VRTX during the recent three months, expressing a mix of bullish and bearish perspectives. The following table encapsulates ...

Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...

Vertex Pharmaceuticals (Nasdaq ... Casgevy’s build-out and further launches of new products in 2025 and 2026, Vertex now seems set for steady profitable growth. There is no dividend.

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ ... helping the company grow product revenue to more than $11 billion in the 2024 full year. It's likely these ...